HUTCHMED (China) Limited, headquartered in Hong Kong, is a leading biopharmaceutical firm focused on advancing targeted therapies and immunotherapies for oncology and immune-related conditions. With a robust research pipeline and deep clinical development expertise, the company is well-positioned to address significant unmet medical needs in cancer treatment. HUTCHMED's strategic partnerships further enhance its potential to leverage the growing global demand for innovative cancer therapies, presenting compelling growth opportunities and value for institutional investors. Show more

Location: CHEUNG KONG CENTER, HONG KONG, HONG KONG, Hong Kong, USA | Website: https://www.hutch-med.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

2.631B

52 Wk Range

$11.51 - $19.50

Previous Close

$14.57

Open

$14.75

Volume

35,019

Day Range

$14.74 - $15.30

Enterprise Value

1.307B

Cash

1.365B

Avg Qtr Burn

-36.45M

Insider Ownership

0.00%

Institutional Own.

3.38%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORPATHYS (Savolitinib) Details Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details Colorectal cancer , Metastatic colorectal cancer, Solid tumor/s, Non-small cell lung carcinoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-453 (FGFR 1/2/3) Details Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Primary immune thrombocytopenia	NDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORPATHYS (Savolitinib) + osimertinib Details EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced Non-small cell lung carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORPATHYS (Savolitinib) (C-MET inhibitor) Details Renal cell carcinoma, Cancer, Gastric cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-306 Details Hematologic malignancies, Blood cancer, Acute myeloid leukemia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) + paclitaxel Details Cancer, Solid tumor/s, Gastroesophageal adenocarcinomas, Gastric cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SULANDA (Surufatinib) Details Solid tumor/s, Neuroendocrine tumor, Pancreatic cancer, Cholangiocarcinoma, Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) + Sintilimab Details Solid tumor/s, Renal cell carcinoma, Cancer, Kidney cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SULANDA (Surufatinib) + Camrelizumab Details Solid tumor/s, Pancreatic cancer, Cancer, Pancreatic ductal adenocarcinoma	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORPATHYS (Savolitinib) + TAGRISSO Details Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tazemetostat Details Follicular lymphoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Amdizalisib (HMPL-689) (PI3K) Details Non-Hodgkin lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELUNATE (Fruquintinib) + Sintilimab Details Solid tumor/s, Cancer, Endometrial cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sovleplenib (HMPL-523) (Syk inhibitor) Details Non-Hodgkin lymphoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-A251 (PI3K/PIKK Inhibitor) Details HER2-Expressing Advanced Solid Tumors	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMPL-506 Details Cancer, Leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.